MSB 8.76% 88.5¢ mesoblast limited

Ann: Update on BLA for Graft Versus Host Disease, page-134

  1. 5,715 Posts.
    lightbulb Created with Sketch. 2058
    He said on the conference call that FDA wasn't going to consider results of any new trials until the potency assays were acceptable and now that hurdle has been achieved, making the next trial possible

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.